Phase 2 study of iadademstat for the treatment of patients with essential thrombocythemia resistant/intolerant to hydroxyurea

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523864-19-00

Enrollment

Registered

2026-02-20

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Thrombocythemia

Brief summary

Percentage of patients achieving a reduction of platelet counts to ≤400x109/L in the absence of any subsequent thrombotic events while maintaining normal platelet counts, at any time during 24 weeks of treatment, Occurrence, severity of Treatment Emergent Adverse Events (TEAEs) (graded using the Common Terminology Criteria for AEs -CTCAE) v 5.0 criteria

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percentage of patients achieving a reduction of platelet counts to ≤400x109/L in the absence of any subsequent thrombotic events while maintaining normal platelet counts, at any time during 24 weeks of treatment, Occurrence, severity of Treatment Emergent Adverse Events (TEAEs) (graded using the Common Terminology Criteria for AEs -CTCAE) v 5.0 criteria	—

Outcome results